For UK clinics selling it as a treatment, the MHRA position now creates direct legal exposure [1]
To view a copy of this licence, visit About this article Cite this article Ryan, D.H., Lingvay, I., Deanfield, J
Neuroprotection: Supports nerve healing and reduces pain signaling
July 23 BPC-157 Proposed use : ulcerative colitis (an inflammatory bowel disease) Outcome : Yes Margin : 8-6 in favor, with one abstention What the FDA was saying : There is a lack of evidence to support using
A counteracting agent may be the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, an anti-ulcer peptide per-orally active (12-15) that may also affect many central disturbances (16-23), efficient in inflammatory bowel disease trials (PL 14736) (24, 25) and various wound treatment (26-28), no toxicity reported (12, 13, 24, 25)) which showed various hepatoprotective effects (29-31)